Total existing-home sales—completed transactions that include single-family homes, townhomes, condominiums and co-ops—rose 3.1% from December to a seasonally adjusted annual rate of 4.00 million in January.
Life Sciences Firm to Relocate to Hawthorne
ELMSFORD—Robert Martin Company’s expansion into serving the needs of the life sciences/health tech industry with the formation of RMC Bio1 is beginning to pay off.
The firm announced that New York City-based Clarapath will be shifting its corporate headquarters from New York City to a building it owns in Hawthorne. Clarapath, a developer of an integrated robotics platform designed to standardize and digitally transform anatomic pathology, has signed a lease for 7,000 square feet at 12 Skyline Drive in Robert Martin’s Mid-Westchester Executive Park in Hawthorne.
Clarapath’s fully automated device will act as the eye, hand and brain of a traditional lab technician and provide better quality biopsy slides, faster turnaround times and lower costs for laboratories. The company will utilize the new space for the development and light manufacturing of its technology, Robert Martin officials stated.
“Covid-19 is accelerating a trend we predicted last year, which is the movement of life sciences and health technologies companies ‘graduating’ out of New York City by expanding into the surrounding suburbs in search of more affordable and flexible spaces,” stated RMC Bio1 Managing Director, Laurence Gottlieb. “Robert Martin Company launched RMC Bio1 last year to take advantage of this emerging trend for the benefit of all Westchester County residents, and I am thrilled the first tenant signed after the launch of this new initiative is a shining example of leading-edge medical technology born and raised in New York State with more to come.”
Clarapath was founded in 2014 as a “spin-out” from Cold Spring Harbor Laboratory and currently operates at the New York Genome Center in SoHo at 101 Sixth Ave. The technology being developed, named SectionStar, takes paraffin tissue blocks as inputs and provides glass slides with sliced tissue as outputs. The device is being developed in close concert with Northwell Health, which is also an investor in the company.
“We are extremely excited to make 12 Skyline Drive our new corporate headquarters,” said Eric Feinstein, CEO of Clarapath. “Making this move to Hawthorne will improve efficiency and collaboration, while providing a first-class work environment for our employees.”
Clarapath is part of RMC Bio1’s redevelopment of 12 Skyline Drive property, which sits within a highly active “innovation district” encompassing New York Medical College and its successful incubator space BioInc@NYMC, Westchester Medical Center and Regeneron Pharmaceuticals’ world headquarters.